Riverbend Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.44M Buy
2,030
+171
+9% +$175K 1.22% 21
2026
Q1
$1.71M Buy
1,859
+71
+4% +$72K 0.98% 25
2025
Q4
$1.92M Buy
1,788
+78
+5% +$74.6K 1.19% 21
2025
Q3
$1.31M Buy
1,710
+50
+3% +$37.2K 0.91% 30
2025
Q2
$1.29M Buy
1,660
+551
+50% +$428K 0.98% 29
2025
Q1
$916K Buy
1,109
+34
+3% +$28.3K 0.82% 37
2024
Q4
$832K Buy
+1,075
New +$890K 0.74% 39

Other funds holding LLY

Riverbend Wealth Management's LLY Position: Q2 2026 in Review

Riverbend Wealth Management increased its Eli Lilly (LLY) stake by 9.2% in Q2 2026, buying an estimated $175K and bringing the position to 2,030 shares worth $2.44M. The position accounts for 1.22% of the portfolio, ranked #21.

Riverbend Wealth Management first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 2,206 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Riverbend Wealth Management held 2,030 shares of Eli Lilly worth $2.44M as of Q2 2026.
  • Riverbend Wealth Management bought 171 Eli Lilly shares in Q2 2026, an estimated $175K.
  • Eli Lilly made up 1.22% of Riverbend Wealth Management's portfolio in Q2 2026, its #21 holding.
  • Riverbend Wealth Management first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 2,206 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Riverbend Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.